- Home
- GLTO vs SISI Comparison
GLTO vs SISI Comparison
Compare GLTO & SISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- SISI
- Stock Information
- Founded
- GLTO 2011
- SISI 1997
- Country
- GLTO Denmark
- SISI China
- Employees
- GLTO N/A
- SISI N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- SISI Medicinal Chemicals and Botanical Products
- Sector
- GLTO Health Care
- SISI Health Care
- Exchange
- GLTO Nasdaq
- SISI Nasdaq
- Market Cap
- GLTO 4.5M
- SISI 4.0M
- IPO Year
- GLTO 2020
- SISI 2016
- Fundamental
- Price
- GLTO $3.21
- SISI $0.14
- Analyst Decision
- GLTO Buy
- SISI
- Analyst Count
- GLTO 1
- SISI 0
- Target Price
- GLTO $10.00
- SISI N/A
- AVG Volume (30 Days)
- GLTO 29.8K
- SISI 13.0M
- Earning Date
- GLTO 08-11-2025
- SISI 09-29-2025
- Dividend Yield
- GLTO N/A
- SISI N/A
- EPS Growth
- GLTO N/A
- SISI N/A
- EPS
- GLTO N/A
- SISI N/A
- Revenue
- GLTO N/A
- SISI $9,601,324.00
- Revenue This Year
- GLTO N/A
- SISI N/A
- Revenue Next Year
- GLTO N/A
- SISI N/A
- P/E Ratio
- GLTO N/A
- SISI N/A
- Revenue Growth
- GLTO N/A
- SISI 1133.26
- 52 Week Low
- GLTO $2.01
- SISI $0.12
- 52 Week High
- GLTO $15.13
- SISI $17.04
- Technical
- Relative Strength Index (RSI)
- GLTO 38.87
- SISI 36.84
- Support Level
- GLTO $3.10
- SISI $0.15
- Resistance Level
- GLTO $3.65
- SISI $0.27
- Average True Range (ATR)
- GLTO 0.31
- SISI 0.02
- MACD
- GLTO -0.06
- SISI 0.01
- Stochastic Oscillator
- GLTO 10.61
- SISI 13.88
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.